Stay updated on Talazoparib Pre-Standard Therapy in BRCA+ Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Talazoparib Pre-Standard Therapy in BRCA+ Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Talazoparib Pre-Standard Therapy in BRCA+ Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now presents the completed Phase 2 study of talazoparib before standard therapy for patients with BRCA-mutated invasive breast cancer. It includes study design and results measures, participant criteria, locations, publications, and study documents.
    Difference
    46%
    Check dated 2026-11-09T13:52:00.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:54:07.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs. It appears above the study page’s 403 error message.
    Difference
    1%
    Check dated 2026-10-26T14:29:02.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site revision label in the page footer changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T14:12:06.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:52:36.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden message instead of the study record content, indicating restricted access to the entry.
    Difference
    18%
    Check dated 2026-09-21T22:25:33.000Z thumbnail image

Stay in the know with updates to Talazoparib Pre-Standard Therapy in BRCA+ Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Talazoparib Pre-Standard Therapy in BRCA+ Breast Cancer Clinical Trial page.